2nd Conference on Sanfilippo Syndrome and Related Diseases 26-28th November 2015, Starling Hotel, Geneva, Switzerland

Day 1 Afternoon

15:00-17:00: Registration and Mixer

17:00-17:30: Welcome speeches

17:30-18:15: Plenary lecture

18:30: Cocktail

Day 2 Morning

8:00-10:00 Session 1: LSD Screening and Diagnosis

1) Keynote presentation

Prof. John Hopwood, Lysosomal Diseases Research Unit, South Australian Health and Medical Research Institute, Adelaide, Australia

2) Newborn screening and selective biochemical screening

Dr. Zoltan Lukacs, Institute of Clinical Chemistry/Dept. of Pediatrics, University Medical Center Hamburg-Eppendorf, Germany

3) Molecular Analysis

Dr. Andreas Gal, Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Germany

4) Diagnostic challenges in Niemann Pick C

Dr. Heiko Runz, Dept. Genetics and Pharmacogenomics, Merck Research Labs, Boston, USA

10:00-10:30 Coffee break

10:30-12:00 Session 2: Treatment options

1) ERT and substrate reduction

Dr. Eugen Mengel, Center for Pediatric and Adolescent Medicine, University Medical Center, Mainz, Germany

2) Stem cell transplantation

Dr. Rob Wynn, Blood and Marrow Transplant Unit, Royal Manchester Children's Hospital, and University of Manchester, UK

3) Virus-based delivery systems for human gene therapy Dr. Alessandra Biffi, San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Hospedale San Raffaele, Milan, Italy

12:00-13:30 Lunch

Day 2 Afternoon

13:30-15:00 Session 3: **Specific clinical aspects of MPS III and new treatment approaches**

- 1) Keynote presentation Intra-cerebral administration of AAV2/5 vector containing human NAGLU cDNA in children with MPSIIIB: results at 12 months of a Phase I/II trial Prof. Marc Tardieu, Paediatric neurology service, INSERM unit 1012, Université Paris South, France
- 2) Natural history

Prof. Frits Wijburg, Dept. of Paediatrics, Academic Medical Centre, Amsterdam, The Netherlands

3) Antibody-directed, receptor-mediated transcytosis technology to treat MPS IIIa and other LSDs

Dr. James Callaway, ArmaGen Inc. Calabasas, CA, USA

4) Gene therapy and other clinical approaches for MPSIIIC Dr. Brian Bigger, Faculty of Medical and Human Sciences, University of Manchester, UK

15:30-16:00 Coffee break

16:00-18:00 Session 4: Clinical trials in MPS and related LSDs

1) Keynote presentation - Use of biomarkers in evaluating response to therapy in clinical trials for LSDs

Prof. Hans Aerts, Department of Biochemistry, Leiden University, The Netherlands

- 2) Gene therapy for MPS IIIA the P1-SAF-301 trial Ms. Samantha Parker, Lysogene, Neuilly-sur-Seine, France
- 3) Planned study of ABX-A and ABX-B for MPS Type A and B **Dr. Tim Miller, Abeona therapeutics, USA**
- 4) Planned clinical studies of non-competitive pharmacological chaperones for GM1-gangliosidosis

Dr. Marc Martinell, Minoryx therapeutics, Barcelona, Spain

Day 3 morning

8:30-10:30 Session 5: Regulations

- 1) The drug development process in rare disease research **Dr. Stéphane Demotz, Dorphan SA, Lausanne, Switzerland**
- 2) The role of patient organisations in shaping rare disease policy Ms. Paloma Tejada, EURORDIS, Paris France
- 3) Patient registries in drug development and regulatory decisions for LSDs Dr. Simon Jones, Willink Unit, Manchester Centre for Genomic Medicine St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester, UK
- 4) Pediatric Perspectives in Drug Development: Switzerland Prof. Dr. Hulya Ozsahin, MD, Exec. MBA Healthcare, Swissmedic-Swiss Agency for Therapeutic Products, Bern, Switzerland

10:30-11:00 Coffee break

11:00-13:00 Session 6: Families

- 1) Genetic counseling and prenatal diagnosis (20 min)

 Dr. Armand Bottani, Dept. Medical Genetics, Geneva University Medical Center,

 Switzerland
- 2) Main highlights of the scientific conference (45 min)
- 3) Round table Q&A session with scientific experts (40 min) Chair: Dr. Armand Bottani

Participants to be confirmed

12:45-14:15 Lunch Departure